CD19 and hematologic disorder: This specific patient population is expected to grow significantly in the near future with increasing use of novel B-cell depleting strategies for hematologic malignancies, such as CD19-directed chimeric antigen receptor T-cell treatment (CAR-T) and anti-B-cell maturation antigen-directed bispecific antibody therapy [20, 21].